elara's pipeline

Target Classes & Opportunities
Hypoxia Signaling Antagonists
The signaling pathways activated by low oxygen availability, or
hypoxia, allow cell adaptation and survival in the hypoxic environment
including angiogenesis. The hypoxic response in tumors mediated
by the Hypoxia Inducible Factor (HIF) is associated with resistance
to radiotherapy and poor clinical outcome.
Deprivation of blood supply to tumors has been
unequivocally validated as a therapeutic strategy in oncology.
Anti-HIF drugs work by preventing development and growth of new
tumor vessels through suppression of the hypoxic response. However,
these drugs do not affect established tumor vasculature creating
the opportunity for enhanced therapeutic benefits with the use
of HIF inhibitors.
ELARA has built up a portfolio of proprietary
highly potent HIF Signaling pathway inhibitors. Examples from
the chemotypes show excellent in vitro activity against
a diverse set of tumor cell lines and show superior pharmacokinetic
and toxicity profile in vivo. Our lead candidate is expected
to enter pre-clinical development in Q1 2009 with first in man
studies initiated in Q1 2010.
Allosteric Kinase
Inhibitors: Aurora
Ground breaking research from EMBL research groups enabled the
identification of a novel allosteric regulatory site of Aurora
A kinase that is essential for proper protein function. In our
Aurora program, we established a proprietary portfolio of allosteric
inhibitor chemotypes
